ES2253753T3
(en)
*
|
1995-06-29 |
2006-06-01 |
Immunex Corporation |
CITOCINE INDUCING APOPTOSIS.
|
US6284236B1
(en)
|
1995-06-29 |
2001-09-04 |
Immunex Corporation |
Cytokine that induces apoptosis
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6046048A
(en)
*
|
1996-01-09 |
2000-04-04 |
Genetech, Inc. |
Apo-2 ligand
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
CA2260767A1
(en)
|
1996-07-19 |
1998-01-29 |
Takeda Chemical Industries, Ltd. |
Fas ligand-like protein, its production and use
|
FR2766713B1
(en)
*
|
1997-08-04 |
1999-09-24 |
Bio Merieux |
PROTEIN FACTOR ASSOCIATED WITH NEURO-DEGENERATIVE AND / OR AUTOIMMUNE AND / OR INFLAMMATORY DISEASE
|
US6346388B1
(en)
|
1997-08-13 |
2002-02-12 |
Smithkline Beecham Corporation |
Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
|
WO1999036535A1
(en)
|
1998-01-15 |
1999-07-22 |
Genentech, Inc. |
Apo-2 ligand
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
EP1820860A3
(en)
*
|
1999-06-02 |
2008-03-19 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
NZ537920A
(en)
|
1999-06-28 |
2006-10-27 |
Genentech Inc |
An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand
|
CA2405709A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
NZ522700A
(en)
|
2000-06-16 |
2006-02-24 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
JP4434580B2
(en)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
Methods for administering / prescribing anti-RSV antibodies for prevention and treatment
|
ES2649037T3
(en)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Molecules with prolonged half-lives, compositions and uses thereof
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
NZ529359A
(en)
|
2001-05-25 |
2007-04-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1499352A4
(en)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Recombinant anti-interleukin-9 antibodies
|
DE60209832T2
(en)
*
|
2002-05-29 |
2007-01-25 |
Charité - Universitätsmedizin Berlin |
A method of identifying Ifn-beta responsive multiple sclerosis patients by determining the expression of Trail
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
RS20050300A
(en)
|
2002-10-16 |
2007-08-03 |
Euro-Celtique S.A., |
Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
|
JP2006524039A
(en)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
Identification and production of antibody containing mutant Fc region and use thereof
|
KR20120035234A
(en)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
Recombinant il-9 antibodies and uses thereof
|
EP1628992A4
(en)
|
2003-05-13 |
2008-04-16 |
Novartis Vaccines & Diagnostic |
Methods of modulating metastasis and skeletal related events resulting from metastases
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
SG10201900535UA
(en)
|
2003-12-23 |
2019-02-27 |
Genentech Inc |
Novel anti-il 13 antibodies and uses thereof
|
MXPA06009072A
(en)
|
2004-02-09 |
2007-03-29 |
Human Genome Sciences Inc |
Albumin fusion proteins.
|
CA2562771C
(en)
|
2004-04-12 |
2013-04-09 |
Medimmune, Inc. |
Anti-il-9 antibody formulations and uses thereof
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
JP5153613B2
(en)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
Antibody framework shuffle
|
CA2605024C
(en)
|
2005-04-15 |
2018-05-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
KR20180002911A
(en)
|
2005-11-04 |
2018-01-08 |
제넨테크, 인크. |
Use of complement pathway inhibitors to treat ocular diseases
|
EP2037961B1
(en)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
EP2029173B1
(en)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2054437A2
(en)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
EP2117571B1
(en)
|
2006-12-08 |
2017-03-08 |
Monopar Therapeutics Inc. |
Urokinase-type plasminogen activator receptor epitope
|
CL2007003661A1
(en)
|
2006-12-18 |
2008-07-18 |
Genentech Inc |
VARIABLE AND LIGHT VARIABLE HEAVY CHAIN REGIONS; NUCLEIC ACIDS THAT CODE THEM; METHOD OF PRODUCTION; ANTI-NOTCH3 ANTIBODIES THAT UNDERSTAND THEM; AND USE OF ANTIBODIES TO TREAT DISEASES RELATED TO THE RECEIVER NOTCH3.
|
EP2068923A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
Antibodies with decreased deamidation profiles
|
US8211858B2
(en)
|
2007-04-27 |
2012-07-03 |
The University Of Toledo |
Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
|
JP5791895B2
(en)
|
2007-05-04 |
2015-10-07 |
テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー |
Genetically engineered rabbit antibody variable domains and uses thereof
|
JP5718637B2
(en)
|
2007-06-21 |
2015-05-13 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and its use
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
SI2195023T1
(en)
|
2007-08-29 |
2018-07-31 |
Sanofi |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
NZ586544A
(en)
|
2007-12-26 |
2012-07-27 |
Vaccinex Inc |
Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
|
US20110033378A1
(en)
|
2008-01-18 |
2011-02-10 |
Medlmmune, Llc. |
Cysteine Engineered Antibodies For Site-Specific Conjugation
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
MX2011002478A
(en)
|
2008-09-07 |
2011-04-05 |
Glyconex Inc |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use.
|
EA027693B1
(en)
|
2008-09-26 |
2017-08-31 |
Токаджен Инк. |
Recombinant replication competent retrovirus having cytosine deaminase activity for gene therapy of cell proliferative disorders
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
CN106432503B
(en)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
Covalent diabodies and uses thereof
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
DK2769737T3
(en)
|
2009-07-20 |
2017-07-24 |
Bristol Myers Squibb Co |
COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
EP2542578A1
(en)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c and brain cancers
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
JP5964300B2
(en)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and its use
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
AU2011293127B2
(en)
|
2010-08-27 |
2016-05-12 |
Abbvie Stemcentrx Llc |
Notum protein modulators and methods of use
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
JP6167040B2
(en)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Design of stable heterodimeric antibodies with mutations in the Fc domain
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
MX361929B
(en)
|
2010-11-19 |
2018-12-19 |
Eisai R&D Man Co Ltd Star |
Neutralizing anti-ccl20 antibodies.
|
MX356400B
(en)
|
2010-12-08 |
2018-05-28 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use.
|
EP2668210B1
(en)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
SA112330278B1
(en)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
Novel modulators and methods of use
|
PL3235508T3
(en)
|
2011-03-16 |
2021-07-12 |
Sanofi |
Compositions comprising a dual v region antibody-like protein
|
JP6145088B2
(en)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
Deimmunized serum binding domain and its use to extend serum half-life
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
CA2849705A1
(en)
|
2011-09-23 |
2013-03-28 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Modified albumin-binding domains and uses thereof to improve pharmacokinetics
|
PL2773671T3
(en)
|
2011-11-04 |
2022-01-24 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
EP3093293A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Anti dll3 antibodies and methods of use thereof
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
EP2869818A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
BR112015001459B1
(en)
|
2012-07-25 |
2023-02-14 |
Celldex Therapeutics, Inc |
ISOLATED ANTIBODY OR FRAGMENT THEREOF, CONJUGATE, USES THEREOF, PHARMACEUTICAL COMPOSITION, POLYNUCLEOTIDE, VECTOR, HOST CELL, ISOLATED CELL, KIT, IN VITRO METHOD TO INHIBIT KIT ACTIVITY, METHOD TO PRODUCE AN ANTIBODY
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
CN104884627A
(en)
|
2012-10-25 |
2015-09-02 |
托卡根公司 |
Retroviral vector with mini-promoter cassette
|
KR102264570B1
(en)
|
2012-11-28 |
2021-06-14 |
자임워크스 인코포레이티드 |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
SI2958944T1
(en)
|
2013-02-22 |
2019-08-30 |
Abb Vie Stemcentrx Llc |
Antidll3-antibody-pbd conjugates and uses thereof
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
ES2761587T3
(en)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
New screening method for the treatment of Friedreich's ataxia
|
EP3338793A1
(en)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
LT3097122T
(en)
|
2014-01-24 |
2020-07-27 |
Ngm Biopharmaceuticals, Inc. |
Antibodies binding beta klotho domain 2 and methods of use thereof
|
KR20170008202A
(en)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
CA2947605A1
(en)
|
2014-05-13 |
2015-11-19 |
Bioatla, Llc |
Conditionally active biological proteins
|
CN106413750B
(en)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties
|
AU2015265457B2
(en)
|
2014-05-28 |
2021-02-18 |
Zymeworks Bc Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
EP3157535A1
(en)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
US10513699B2
(en)
|
2014-09-03 |
2019-12-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
US10766959B2
(en)
|
2014-12-11 |
2020-09-08 |
Pierre Fabre Medicament |
Anti-C10ORF54 antibodies and uses thereof
|
CA2977687C
(en)
|
2015-02-24 |
2024-02-13 |
Hwai Wen Chang |
Conditionally active proteins
|
CN114504652A
(en)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
Antibodies, uses and methods
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
KR20180069839A
(en)
|
2015-10-08 |
2018-06-25 |
자임워크스 인코포레이티드 |
Antigen-binding polypeptide constructs including kappa and lambda light chains and uses thereof
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
EP3383908A1
(en)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
JP7369038B2
(en)
|
2017-05-31 |
2023-10-25 |
ストキューブ アンド シーオー., インコーポレイテッド |
Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof
|
JP2020522512A
(en)
|
2017-05-31 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Method of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
JP2020522562A
(en)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand
|
JP7245793B2
(en)
|
2017-06-30 |
2023-03-24 |
ザイムワークス ビーシー インコーポレイテッド |
Stabilized chimeric Fab
|
JP7165193B2
(en)
|
2017-11-27 |
2022-11-02 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
Humanized antibody targeting human tissue factor
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
CN113874392A
(en)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
Engineered antibodies
|
JP2022532928A
(en)
|
2019-05-24 |
2022-07-20 |
サノフイ |
Methods for treating systemic scleroderma
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|